An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Latest Information Update: 23 Mar 2025
At a glance
- Drugs LCAR-AIO (Primary)
- Indications Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica
- Focus Adverse reactions; Pharmacokinetics
- 14 Mar 2025 New trial record